EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Naproxen adjunct to fluoxetine for moderate‐to‐severe obsessive‐compulsive disorder: A randomized, double‐blind, placebo‐controlled trial

Ahmad Shamabadi iD, Zahra Motavalian, Yalda Farahmand, Kimia Farahmand, Razman Arabzadeh Bahri, Sanaz Askari, Sahar Ansari, Mohammadali Fallahzadeh, Mohammdreza Shalbafan, Shahin Akhondzadeh iD

Psychiatry and Clinical Neurosciences · 2024

DOI: 10.1111/pcn.13748 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Psychiatry and Clinical Neurosciences, 2024. Verfasst von Ahmad Shamabadi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Fluoxetine, Obsessive-Compulsive Disorder, Naproxen, Drug Therapy, Combination. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Tehran University of Medical Sciences and Health Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Current treatments for obsessive‐compulsive disorder (OCD) encounter resistance and limiting adverse events, necessitating novel therapeutic strategies. This study aimed to investigate the benefits of naproxen, a medication with effects on inflammation and neuronal function, on OCD.

Methods

One hundred and four OCD outpatients with a Yale‐Brown Obsessive‐Compulsive Scale (Y‐BOCS) score of >21 were equally assigned to receive fluoxetine plus either naproxen 250 mg or matched placebo q12hr. Patients were assessed using the Y‐BOCS by recording the subscale scores at baseline and weeks 5 and 10 to evaluate efficacy. They were also assessed in terms of tolerability.

Results

Data from 96 patients were analyzed. The baseline characteristics were comparable between the groups. There were significant time‐treatment interaction effects on the obsession subscale ( = 0.055) and total ( = 0.043) scores of Y‐BOCS. Reductions in the obsession subscale and total scores of Y‐BOCS were significantly greater in the fluoxetine plus naproxen group until the endpoint (Cohen's d = 0.560 and Cohen's d = 0.477, respectively). However, the difference in compulsion subscale score changes between the groups was not significant. Respondents with a reduction of ≥35% in Y‐BOCS total scores were significantly more in the fluoxetine plus naproxen group (80.0% versus 47.8%). The side effect frequencies were comparable between the groups.

Conclusion

Naproxen, adjunct to fluoxetine, outperformed adjunctive placebo in treating obsession and total symptoms of OCD patients in a safe and tolerable manner. Clinical trial registration The study protocol was registered and published in the Iranian Registry of Clinical Trials (http://www.irct.ir; registration number IRCT20090117001556N139).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluoxetineObsessive-Compulsive DisorderNaproxenDrug Therapy, CombinationSelective Serotonin Reuptake InhibitorsHumansMaleFemaleAdultDouble-Blind MethodYoung AdultMiddle AgedAnti-Inflammatory Agents, Non-SteroidalOutcome Assessment, Health Care

Stichwörter der Autor:innen

adverse drug reactioncombination drug therapyneuroimmunomodulationnonsteroidal anti‐inflammatory agentsrandomized controlled trial

Substanzen

FluoxetineNaproxenSelective Serotonin Reuptake InhibitorsAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Mental Health Research Center, Psychosocial Health Research Institute, Department of Psychiatry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Psychosomatic Research Center, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Ahmad Shamabadi, Shahin Akhondzadeh

Förderung

  • Tehran University of Medical Sciences and Health Services

Zitieren

APA

Shamabadi, A., Motavalian, Z., Farahmand, Y., Farahmand, K., Arabzadeh Bahri, R., Askari, S., Ansari, S., Fallahzadeh, M., Shalbafan, M., & Akhondzadeh, S. (2024). Naproxen adjunct to fluoxetine for moderate‐to‐severe obsessive‐compulsive disorder: A randomized, double‐blind, placebo‐controlled trial. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13748

Vancouver

Shamabadi A, Motavalian Z, Farahmand Y, Farahmand K, Arabzadeh Bahri R, Askari S, et al. Naproxen adjunct to fluoxetine for moderate‐to‐severe obsessive‐compulsive disorder: A randomized, double‐blind, placebo‐controlled trial. Psychiatry and Clinical Neurosciences. 2024. doi:10.1111/pcn.13748

BibTeX
@article{Shamabadi2024,
  author = {Shamabadi, Ahmad and Motavalian, Zahra and Farahmand, Yalda and Farahmand, Kimia and Arabzadeh Bahri, Razman and Askari, Sanaz and Ansari, Sahar and Fallahzadeh, Mohammadali and Shalbafan, Mohammdreza and Akhondzadeh, Shahin},
  title = {Naproxen adjunct to fluoxetine for moderate‐to‐severe obsessive‐compulsive disorder: A randomized, double‐blind, placebo‐controlled trial},
  journal = {Psychiatry and Clinical Neurosciences},
  year = {2024},
  doi = {10.1111/pcn.13748}
}
Kostenlos starten →